| 【Company Research】CSPC Pharmaceutical (1093 HK) - Resilient BD momentum offsets sales pressure |
| 【Company Research】Li Ning (2331 HK) - Conservative guidance but quite expected |
| 【Company Research】Samsonite (1910 HK) - Weak FY24 dragged by TUMI and American Tourister, 1Q25 sales to decline LSD-MSD |
| 【Company Research】InnoCare Pharma (9969 HK) - Orelabrutinib-led growth with strategic pipeline advancements in oncology and autoimmune |
| 【Company Research】Carote Ltd (2549 HK) - Still subject to numerous macro risks |
| 【Company Research】DPC Dash (1405 HK) - Long-term story intact but let’s just play safe |
| 【Company Research】Innovent Biologics (1801 HK) - Entering sustainable profitability with a global innovation engine |
| 【Company Research】EHang Holdings (EH US) - Obtained the first-ever OC for commercial operations |
| 【Company Research】GAC Group (2238 HK/601238 CH) - Can new management turn around homegrown brands? |
| 【Company Research】Great Wall Motor (2333 HK/601633 CH) - Wey could be key to FY25 earnings growth |
公司地址：香港中環花園道三號冠君大廈45-46樓
電話：（852） 3900-0888 傳真：（852） 3761-8788
招銀國際版權所有 Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
